PolyPid reports Q3 results (PYPD:NASDAQ)

PolyPid reported Q3 GAAP EPS of -$0.24, with a net loss of $5.8M, down from $7.5M a year prior. Cash reserves increased to $15.5M from $12.9M. Results may not align with estimates.

Original reporting
Published Nov 11, 2026, 12:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 12:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
PolyPid reports Q3 results (PYPD:NASDAQ) — source image
Decision brief

The 30-second read

$PYPDBearishLow
01

Why it matters

The disclosed loss and negative EPS are new information that could move the stock.

02

Market read

First earnings report for the quarter; micro‑cap with modest financials.

03

What to watch

Cash balance of $15.5M may provide runway for upcoming R&D spending.

Relevance 6/10Novelty 6/10Timing: after‑hours release

Background

PolyPid (NASDAQ:PYPD) released its Q3 2026 earnings via a press release.

Company-level read

Ticker impact

$PYPDBearishMedium confidence
Context

Q3 GAAP EPS of -$0.24 and net loss of $5.8M were disclosed for the first time.

Expected impact

likely downside as market prices in the loss and weak EPS

Evidence & confidence

First‑time earnings release with a loss larger than prior year; micro‑cap stocks typically react sharply to earnings misses.

Market effects

Minimal impact on the broader biotech sector.

Limited to U.S. micro‑cap investors.

Low

Counterpoint

If the market overreacts to the loss, a short‑term bounce could occur.

Key entities

  • PolyPid

    Biotech firm listed on NASDAQ.

Related articles

$PYPDMed

PolyPid Ltd. (PYPD): Financial results for Q3 2026

PolyPid Ltd. (PYPD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results D-PLEX₁₀₀ NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations Ongoing Expanding D-PLEX₁₀₀ Globally: MAA Submitted and Validated

$PYPDMedAI 8/10

PolyPid unveils PD01B for diabetic foot infection treatment

PolyPid Ltd. (NASDAQ:PYPD) introduced PD01B, a product candidate for treating moderate to severe diabetic foot infections, using its Kynatrix delivery technology. The company plans to initiate a first-in-human study in the second half of 2027. PolyPid also expects a decision on its lead product D-PLEX₁₀₀ by November 28, 2026, with a potential U.S. launch in early 2027, subject to FDA approval.

$PYPDHighAI 8/10

Oppenheimer initiates PolyPid stock coverage with outperform rating

Oppenheimer initiated coverage on PolyPid (NASDAQ:PYPD) with an outperform rating and a $10.00 price target. The stock is up 47% over the past year, with a Strong Buy consensus and targets ranging from $8 to $14. PolyPid's D-PLEX100 reduced surgical site infections by 60% in a Phase 3 study and is under FDA Priority Review. The company reported a narrower Q2 2026 loss of $0.35 per share, beating expectations.

$PYPDMed

What PolyPid’s Bold Moves in Europe Could Mean for D-PLEX₁₀₀’s Global Potential (NASDAQ: PYPD) By FinanceWire

PolyPid (NASDAQ: PYPD) announced European Medicines Agency validation of its D-PLEX₁₀₀ Marketing Authorization Application and regained full European commercialization rights. The company's stock rose 15% premarket. D-PLEX₁₀₀, a surgical site infection treatment, has positive Phase 3 data and FDA Priority Review in the U.S. PolyPid aims to partner in Europe on stronger terms than its previous agreement.